leisure time -WSS

leisure time

author：explore 2025-09-03 09:26:02 - browse：95

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Organ transplantation is at a crossroads. Major reform is needed

WSS

Drastic changes should bring profitability, startup health insurers say

What to know about Saharan dust affecting the US and how it can affect health

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

In same hospitals, Black patients receive fewer opioids than white patients

entertainment

leisure time

focus

How one medical school became remarkably diverse

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

What to know about Saharan dust affecting the US and how it can affect health

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Psychedelics group wrestles with new pharma identity

Court strikes down limits on filming of police in Arizona

Drug repurposing or repositioning? The language matters

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

focus

Providers still hesitate to prescribe buprenorphine, study finds

A biotech analyst on neuroscience, placebo effect, not over

Wegovy’s successful heart trial raises vital question about weight loss

Court strikes down limits on filming of police in Arizona

Caitlin Bernard's story shows physicians can't shy from advocacy

Methadone doses haven’t kept up in the age of fentanyl

focus

Wikipedia

leisure time

focus